focuses on metabolic disorders, including pre-diabetes and obesity. The development of full diabetes is generally preceded by a period characterized by impaired insulin control of triglycerides and glucose levels. It is estimated that the number of individuals worldwide with impaired glucose tolerance is about 314 million. Insulin resistance may be present in 25% of the non-diabetic population, with an estimated conversion rate from an insulin resistant state to type 2 diabetes of 2-12% per year. An oriental diet has been associated with the significantly lower rates of insulin resistance and diabetes. Extensive epidemiological and clinical studies attributed soy consumption to be linked to this protective metabolic effect. Laflavon™ improves insulin metabolism control in pre-diabetes and reduces elevated triglyceride levels. A second product is expected to follow later in 2010.
Laflavon™ is a proprietary blend of soy extracts designed to target the liver and improve insulin metabolism.